|Bid||38.00 x 1100|
|Ask||42.25 x 900|
|Day's Range||41.09 - 41.83|
|52 Week Range||25.10 - 45.02|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-2.48%|
|Beta (5Y Monthly)||1.40|
|Expense Ratio (net)||0.50%|
An exchange traded fund that focuses on medical breakthroughs helps investors gain exposure to some of the cutting edge innovations in the healthcare industry.
The ALPS Medical Breakthroughs ETF (SBIO) was a star performer among healthcare ETFs last year and with small- and mid-cap members of that sector looking poised to renew bullish trends this year, SBIO could again deliver for investors. SBIO focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III trials. The component holdings have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials.
While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.